Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model

Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion

(2017) Ranjeet Prasad Dash et al.   XENOBIOTICA

Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy

(2014) V Sinha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes

(2014) Fen Jiang et al.   PSYCHOPHARMACOLOGY

Inhibition of cytochrome P450 by ethambutol in human liver microsomes

(2014) Sang Yoon Lee et al.   TOXICOLOGY LETTERS

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

(2013) Thomayant Prueksaritanont et al.   AAPS Journal

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

(2013) Marco Siccardi et al.   CLINICAL PHARMACOKINETICS

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

(2013) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

PBPK as a tool in regulatory review

(2012) Shiew-Mei Huang   BIOPHARMACEUTICS & DRUG DISPOSITION

The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review

(2012) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2B6 and Bupropion’s Smoking-Cessation Pharmacology: The Role of Hydroxybupropion

(2012) A Z X Zhu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials

(2012) R Leong et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions

(2012) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Application of PBPK modelling in drug discovery and development at Pfizer

(2011) Hannah M Jones et al.   XENOBIOTICA

Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling

(2010) Nathalie Perdaems et al.   CLINICAL PHARMACOKINETICS

Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency

(2010) C K Yeung et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model

(2010) S. Yamazaki et al.   DRUG METABOLISM AND DISPOSITION

Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice

(2010) M. I. Damaj et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Qualitative Analysis of the Role of Metabolites in Inhibitory Drug−Drug Interactions: Literature Evaluation Based on the Metabolism and Transport Drug Interaction Database

(2009) Nina Isoherranen et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite

(2009) X. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam

(2009) Karen Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

The Simcyp®Population-based ADME Simulator

(2009) Masoud Jamei et al.   Expert Opinion on Drug Metabolism & Toxicology

Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates

(2009) Frederique Fenneteau et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results

(2009) Marylore Chenel et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction

(2008) M. J. Reese et al.   DRUG METABOLISM AND DISPOSITION

A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

(2008) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION

The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling

(2008) Motohiro Kato et al.   PHARMACEUTICAL RESEARCH